Alcon files travoprost/timolol combo
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA has accepted Alcon's NDA for a fixed combination of travoprost 0.004%/timolol 0.5% (TTFC) for the treatment of glaucoma, the firm announces Jan. 25. According to preliminary data presented at the Royal Hawaiian Eye Meeting in January, TTFC reduced intraocular pressure 2 mmHg more than travoprost alone at 8 a.m. in one study. In two other Phase III studies, TTFC was not statistically different from concomitant therapy at the 8 a.m. time points "and at most of, but not all, the other measured time points." Safety was comparable to concomitant dosing in all three studies. The firm estimates approximately 50% of U.S. glaucoma patients use two or more agents...
You may also be interested in...
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.